European Archives - Page 906 of 1449 - European Medical Journal

EMJ Podcast: Neuroscience meets NASA

This week, Jonathan sits down with Professor Babak Kateb, Chairman and CEO, Society for Brain Mapping and Therapeutics, to discuss the potential of cross-discipline collaboration, and reveal what he thinks will be the spaces to watch in neurology and research.

Pulling away from push marketing

While pharmaceutical marketers used to rely heavily on push marketing, since the pandemic, a call to move to pull advertising has prevailed. How can pharma further engage the medical affairs function to draw in doctors with tailored, scientific content that is targeted and trustworthy?

Preparing for the next pandemic

The pharmaceutical industry could have been better prepared for the COVID-19 pandemic. What did they learn that will help them respond better in the future?

A debate on digital transformation

In this roundtable, three thought leaders detail the barriers in the way of digital transformation and outline their vision for the future.

What lessons can pharma learn from Silicon Valley?

How can pharma transform its approach to patients by introducing digital platforms and virtual care into their spaces?

Finding Humanity with AI

How can AI help MA retain their human touch as the industry reimagines the field and creates a best-in-class function?

A Novel Algorithm to Treat Chronic Coronary Total Occlusions

In this webinar, Pierfrancesco Agostoni, Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium presents a simpler and more efficient approach for percutaneous coronary intervention (PCI) of chronic coronary total occlusion (CTO), termed the Minimalistic Hybrid Approach (MHA). Agostoni discusses how MHA helps to downsize the set-up procedure but also helps to achieve minimal invasiveness by improving elements such as the access site, dual injection, and introducer size, while at the same time maintaining the efficiency and success rate of the classic algorithm approach.

EMJ Hematology 9 [Supplement 3] 2021 Feature Image

FLT3 Mutations in Patients with Acute Myeloid Leukaemia: The Importance of Identification and Monitoring for Prognostic Determination and the Selection of Optimal Treatment Strategies

Mutations in FLT3 are the most common genetic alteration in AML. Patients with a FLT3 internal tandem duplication (ITD) mutation subtype have poor prognosis, especially when there is a high allelic burden.

EMJ Hematology 9 [Supplement 3] 2021 Feature Image

EMJ Hematology 9 [Supplement 3] 2021

In this supplement to EMJ Hematology, two leading haematologists, Prof Adriano Venditti and Prof Lars Bullinger, discussed the management…

EMJ Podcast: FLT3 Mutations in Patients with AML

In this episode, we discuss the treatment of patients who have acute myeloid leukemia (AML) as well as FMS-like tyrosine kinase 3 gene (FLT3) mutations.